SCA
ADCT icon

Snowden Capital Advisors’s ADC Therapeutics ADCT Stock Holding History

Snowden Capital Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,323
Closed -$389K – 2031
2021
Q3 		$389K Buy
+14,323
New +$367K 0.02% 607

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Snowden Capital Advisors's ADCT Position: Q4 2021 in Review

Snowden Capital Advisors sold out of ADC Therapeutics (ADCT) in Q4 2021, closing a stake of 14,323 shares — an estimated $389K sold.

Snowden Capital Advisors first reported a position in ADCT in Q3 2021 and held it in 1 quarter. The position peaked at $389K in Q3 2021. 55 funds tracked by Wall St. Rank hold ADCT as of Q4 2021.

  • Snowden Capital Advisors reported no remaining ADC Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Snowden Capital Advisors sold 14,323 ADC Therapeutics shares in Q4 2021, an estimated $389K.
  • Snowden Capital Advisors first reported a position in ADC Therapeutics in Q3 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's ADC Therapeutics position peaked at $389K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2021.

Based on Snowden Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.